Cardiovascular disease in renal failure

Minerva Urologica e Nefrologica

Volumn 56, Issue 3, 2004, Pages 279-288

  Guerin, A P ^a,b   Adda, H ^a   London, G M ^a   Marchais, S J ^a  

^a Hopital Manhes   (France)

^b Centre Hospitalier Manhes   (France)

Author keywords

Arteries, physiopathology; Hypertrophy, left ventricular; Kidney failure, chronic

Indexed keywords

ADAPTATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DEATH; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART STRESS; HEART VENTRICLE PRESSURE; HEMODYNAMICS; KIDNEY FAILURE; PREVALENCE; REVIEW;

ANEMIA; ARTERIOVENOUS SHUNT, SURGICAL; FIBROSIS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MYOCARDIUM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 4544226113     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Foley RN, Herzog CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients. The United States Renal Data System Wave 2 Study. Kidney Int 2003;63:1462-7.
2. London GM, Marchais SJ, Guerin AP, Fabiani F, Metivier F. Cardiovascular function in hemodialysis patients. In: Grunfeld JP, Bach JF, Funck-Brentano JL, Maxwell MH, editors. Advances in nephrology. St. Louis: Mosby-Year Book; 1991;vol. 20.p.249-73.
3. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-90.
4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995;5:2024-31.
5. Sadoshima J, Izumo S. The cellular and molecular response to cardiac myocytes to mechanical stress. Annu Rev Physiol 1997;59:551-71.
6. nd ed. Philadelphia: Lippincott Williams and Wilkins; 2000.p.41-65.
7. Astorri E, Bolognesi R, Colla B, Chizzola A, Visioli O. Left ventricular hypertrophy: a cytometryc study on 42 human hearts. J Mol Cell Cardiol 1977;9:763-75.
8. Ganz P, Braunwald E. Coronary blood flow and myocardial ischemia. In: Braunwald E, editor. Heart disease. 5th ed. Philadelphia: WB Saunders; 1997.p.1161-83.
9. O'Brien PJ, O'Grady M, McCutcheon PJ, Shen H, Nowak L, Horne RD et al. Myocardial myoglobin deficiency in various models of congestive heart failure. J Mol Cell Cardiol 1993;24:721-30.
10. Wanatabe H, Ohtsuka S, Kakihana M, Sugishita Y. Coronary circulation in dogs with an experimental decrease in aortic compliance. J Am Coll Cardiol 1993;21:1497-506.
11. Weber KT, Brilla CG, Campbell SE, Zhou G, Matsubara L, Guarda E. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press 1992;1:75-85.
12. Nicoletti A, Michel J-B. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res 1999;41:532-43.
13. Dorn GW II, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res 2003;92:1171-5.
14. Levin A, Djurdjef O, Barett B, Burgess E, Carlisle E, Ethier J et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 2001;38:1938-407.
15. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1992;47:186-92.
16. Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol 2000;14:898-902.
17. Stewart JA, Foster J, Cowan M, Rooney E, McDonagh T, Dargie HJ et al. Echocardiography overestimates left ventricular mass index in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 1999;56:2248-53.
18. Zocalli C, Benedetto FA, Mallamaci F, Tripepi G, Giagone G, Cataliotti A et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001;12:2768-74.
19. London GM, Parfrey PS. Cardiac disease in chronic uremia: pathogenesis. Adv Ren Replace Ther 1997;4:194-211.
20. Chaignon M, Chen WT, Tarazi RC, Bravo EL, Nikamoto S. Effect of hemodialysis on blood volume distribution and cardiac output. Hypertension 1981;3:327-32.
21. Zocalli C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A et al., Creed Investigators. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001;12:1508-15.
22. Ozkahya M, Toz H, Ozerkan F, Duman S, Ok E, Basci A et al. Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol 2002;15:655-60.
23. Faguli RM, Reboldi G, Quintaliani G, Pasini P, Ciao G, Cicconi B et al. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 2001;38:371-6.
24. Galland R, Treager J, Arkouche W, Delawari E, Fouque D. Short daily hemodialysis and nutritional status. Am J Kidney Dis 2001;37 Suppl 2:S95-8.
25. Maduell F, Navarro V, Torregrosa E, Rius A, Dicenta F, Cruz MC et al. Change from three times on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int 2003;64:305-13.
26. Ahearn DJ, Maher JF. Heart failure as a complication of hemodialysis fistula. Ann Intern Med 1972;70:201-4.
27. Noma K, Brandle M, Rupp H, Jacob R. Left ventricular performance in rats with chronic cardiac overload due to arterio-venous shunt. Heart Vessels 1990;5:65-70.
28. Ori Y, Korzets A, Katz M, Erman A, Weinstein T, Malmachi T et al. The contribution of an arteriovenous access for hemodialysis to left ventricular hypertrophy. Am J Kidney Dis 2002;40:745-52.
29. Unger P, Wissing KM, de Pauw L, Neubauer J, van de Borne P. Reduction of left ventricular diameter and mass after surgical arteriovenous fistula closure in renal transplant recipients. Transplantation 2002;74:73-9.
30. Rosenthal DS, Braunwald E. Hematological-oncological disorders and heart disease. In: Braunwald E, editor. Heart disease: textbook of cardiovascular medicine. 4th ed. Philadelphia: WB Saunders; 1997.p.1786-808.
31. Levin A, Thompson CR, Ethier J, Carlisle EJF, Tobe S, Mendelssohn D et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34.
32. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
33. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientes A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997;29:541-7.
34. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y et al. Cardiovascular effects of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35:250-6.
35. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-35.
36. Silverberg D, Wexler D, Blum M, Iaina A. The cardio-renal syndrome: does it exist? Nephrol Dial Transplant 2003;18 Suppl 8:7-12.
37. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissennson AR, Okamoto DM et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoeitin. New Engl J Med 1998;339:584-90.
38. Hutting J, Kramer W, Schutterle G. Analysis of left ventricular changes associated with chronic hemodialysis: a non invasive follow up study. Nephron 1988;49:284-90.
39. Safar ME. Pulse pressure, arterial stiffness and cardiovascular risk. Curr Opin Cardiol 2000;15:258-63.
40. Klassen P, Lowerie EG, Reddan DN, DeLong ER, Coladonto JA, Szczech LA et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002;287:1548-55.
41. Tozawa, M, Iseki K, Iseki C, Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 2002;61:717-26.
42. London GM, Guerin AP, Marchais SJ. Pressure overload: cardiomyopathy in end-stage renal disease. Curr Opin Nephrol Hypertens 1999;8:179-86.
43. Guerin AP, Pannier B, Marchais SJ, Metivier F, London GM. Arterial remodeling and cardiovascular function in end-stage renal disease. In: Grünfelf JP, Bach JF, Kreiss H, Maxwell MH, editors. Advances in nephrology. St-Louis: Mosby Year Book 1998;vol. 27.p.105-9.
44. London MG, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F et al. Aortic and large artery compliance in end-stage renal disease. Kidney Int 1990;37:137-42.
45. Matsumoto Y, Hamada M, Hiwada K. Aortic distensibility is closely related to the progression of left ventricular hypertrophy in patients receiving hemodialysis. Angiology 2000;51:933-41.
46. Blacher J, Guerin AP, Pannier B, Marchaius SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-9.
47. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001;38:434-8.
48. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-21.
49. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sidr D et al. Coronary artery calcification in young adults with renal disease who are undergoing dialysis. New Engl J Med 2000;342:1478-83.
50. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-42.
51. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-40.
52. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M et al. Cardiac and arterial alterations in end-stage renal disease. Kidney Int 1996;50:600-8.
53. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis. Am J Soc Nephrol 2001;12:2759-67.
54. Amann K, Breitbach M, Ritz G, Mall G. Myocytes/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998;9:1018-22.
55. Amann K, Kronenberg G, Gehlen F, Wessels S, Orth SR, Munter K et al. Cardiac remodeling in experimental renal failure: an immuno-histochemical study. Nephrol Dial Transplant 1998;13:1958-66.
56. Amann K, Gassmann P, Buzello M, Orth SR, Törnig J, Gross ML et al. Effects of ACE-inhibition and bradykinin antagonism on cardiovascular changes in uremic rats. Kidney Int 2000;58:153-61.
57. Vlahakos DV, Hahalis G, Vassilakos P, Marathias KP, Geroulanos S. Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol 1997;8:1764-70.
58. Sato A, Funder JW, Sarute T. Involvement of aldosterone in left ventricular hypertrophy of patients in end-stage renal failure treated with hemodialysis. Am J Hypertens 1999;12:867-73.
59. London GM, Pannier B, Guerin AP, Marchais SJ, Safar EM, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance and wave reflection in end-stage renal disease: comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994;90:2786-96.
60. Amann K, Münter K, Wessels S, Wagner J, Balajew V, Nabokov A et al. Endothelin A receptor blockade prevents capillary/myocytes mismatch in the heart of uremic animals. J Am Soc Nephrol 2000;11:1691-9.
61. Demuth K, Blacher J, Guerin AP, Benoit MO, Moatti N, Safar ME et al. Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrol Dial Transplant 1998;13:375-83.
62. Amann K, Wiest G, Klaus G, Ritz G, Mall G. A role of parathyroid hormone for the activation of cardiac fibroblast in uremia. J Am Soc Nephrol 1994;4:1814-9.
63. Harnett JD, Foley RN, Kent GM, Barre PE, Murray DC, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884-90.
64. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998;54:1720-5.
65. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Serial changes in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000;11:912-6.
66. Canella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialysed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997;30:659-64.
67. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987-92.